Introduction
Mouse and human airway epithelial cells express protease-activated receptor-2 (PAR 2 ) (Cocks et al., 1999; Asokananthan et al., 2002; De Campo and Henry, 2005) , which when activated by either trypsin or the mouse PAR 2 peptide SLIGRL, release prostaglandin E 2 (PGE 2 ) (Lan et al., 2001; Asokananthan et al., 2002; De Campo and Henry, 2005) to cause airway smooth muscle relaxation (Cocks et al., 1999; Chow et al., 2000; Lan et al., 2001; De Campo and Henry, 2005) and inhibition of immune cell trafficking (Moffatt et al., 2002; De Campo and Henry, 2005) .
However, some effects of PAR 2 peptides have been claimed to be independent of PAR 2 activation (Moffatt, 2004) , including mediator release from mast cells (Stenton et al., 2002) and contractions in endothelium-intact umbilical vein tissue . In mice, which are commonly used to model airway inflammatory disease, precise roles for PAR 2 in airway physiology and pathology remain controversial. While some studies have shown clear antiinflammatory protective effects, including a range of PGE 2 -dependent mechanisms (Cocks et al., 1999; Cocks and Moffatt, 2000; De Campo and Henry, 2005) , others have reported proinflammatory actions of PAR 2 in the airways (Schmidlin et al., 2002; Ebeling et al., 2005; Su et al., 2005) . One of the main roles for epithelial PAR 2 appears to be activation of mucosal chloride (Cl -) secretion. This has been shown to occur in dog pancreatic duct epithelial cells (Nguyen et al., 1999) , rat jejunum (Vergnolle et al., 1998) , porcine ileum (Green et al., 2000) , mouse distal colon (Cuffe et al., 2002) and monolayers of human cultured bronchial epithelial cells (Danahay et al., 2001) . Such an increase in Cl -secretion would maintain the protective layer underneath the mucous and as such aid in the efficient removal of inhaled antigens and has been proposed as a possible protective role of epithelial PAR 2 . In the mouse trachea, This article has not been copyedited and formatted. The final version may differ from this version. 5 Kunzelmann et al (2005) reported that PAR 2 located on the basolateral surface of epithelial cells couple to basolateral K + channels and mucosal Cl -channels to mediate net Cl -secretion into the lumen of the airways. They also suggested that these basolateral PAR 2 , as well as apical PAR 2 are coupled to the production of PGE 2 to mediate smooth muscle relaxation. As in our previous study (Cocks et al., 1999) , Kunzelmann et al (2005) similarly reported that PAR 2 are predominantly expressed on the apical surface of mouse tracheal epithelial cells. Activation of these apicallyexpressed PAR 2 , however, with either trypsin or SLIGRL, did not have any effect on ion conductance (Kunzelmann et al., 2005) . In the present study we found an increase in Cl -conductance to SLIGRL in the mouse trachea that was not PGE 2 -dependent and was not mimicked by trypsin or affected by prior exposure to high concentrations of trypsin. Also, the supposedly inactive PAR 2 peptide LSIGRL (Lindner et al., 2000; Fiorucci et al., 2001; Stenton et al., 2002) The preparations were then clamped at a potential difference of zero volts to record short circuit current (I SC ), a measure of the net ionic flux across the preparation. Once mounted, the preparation was allowed to equilibrate (> 20 min) until I SC was stable and any antagonists to be used were added for at least 15 min prior to challenge with agonists.
Mouse tracheal and rat aorta smooth muscle contractility studies. Mouse tracheae (isolated as described above) and thoracic aortae from male Sprague-Dawley rats (200 -300 g) were cut into 3 mm rings and mounted on stainless steel hooks in Krebs-filled organ baths maintained at 37°C and continuously bubbled with 95% O 2 /5% CO 2 . One hook was attached to a micrometredriven anchor in the bath, whilst the other hook was attached to a force transducer for isometric recording of aortic and trachealis muscle tone. After a 30 min equilibration period, 0.5 and 1.0 g tension were applied to the trachea and aorta respectively and the preparations then allowed to return to a steady plateau (> 20 min) before the maximal contractile capacity of the preparation (F max ) was determined by contracting the trachea with 10 µM acetylcholine and the aorta with 
Results
Tension and short circuit current (I SC ) responses to trypsin and PAR peptides. In isometric tension studies of mouse airways, trypsin (0.01 -3 U.ml -1 ) caused concentration-dependent relaxations of mouse trachea ( Figure 1 ). Trypsin is known to cleave the N-terminus of PAR receptors, creating tethered agonist ligands that activate PARs, leading to tracheal relaxation (Cocks et al., 1999; Chow et al., 2000; Lan et al., 2001) . Similar relaxant responses produced by the PAR 2 peptide agonist, the isolated N-terminal hexapeptide of rodent PAR 2 , SLIGRL (0.1 -30 µM), were prevented if the preparation was initially desensitised to trypsin (3 U.ml -1 , Figure 1 ).
However, in the Ussing chamber assay, using an identical protocol, trypsin failed to either elicit a response or prevent I SC responses to SLIGRL ( Epithelium-dependent smooth muscle relaxations to trypsin and SLIGRL in the tracheal mechanical assay (Figures 1 & 4) were within the previously reported range (Cocks et al., 1999) with EC 50 of 0.5 ± 0.1 U.ml -1 and pEC 50 of 5.6 ± 0.1 respectively. Two novel PAR 2 peptide agonists, SLIGRT (pEC 50 5.9 ± 0.2) and SLCGRL (pEC 50 5.3 ± 0.2), were approximately 6-and This article has not been copyedited and formatted. The final version may differ from this version. 20-fold less potent respectively than SLIGRL (pEC 50 6.4 ± 0.1) in causing endotheliumdependent relaxation of the rat aorta preparation (Figure 3 ), which has previously been shown to relax to SLIGRL via PAR 2 in an endothelium-dependent manner (Hwa et al., 1996; ). Also we confirmed that a recently reported stable PAR 2 peptidomimetic agonist, 2-furoyl-LIGRL, was more potent (pEC 50 7.3 ± 0.1) than SLIGRL in this assay (Kawabata et al., 2004) . By contrast another novel PAR 2 peptide agonist SLSGRT and the commonly used partial scramble peptide for SLIGRL, LSIGRL (Lindner et al., 2000; Fiorucci et al., 2001; Stenton et al., 2002) , were both inactive in the aorta up to 100 µM ( Figure 3 ). Thus, an estimated rank order of potency for these peptides in the rat aortic endothelium-dependent relaxation assay was 2-furoyl-LIGRL > SLIGRL > SLIGRT > SLCGRL with LSIGRL and SLSGRT inactive. Also in the aorta, responses to 2-furoyl-LIGRL, SLIGRL, SLIGRT and SLCGRL were abolished if preparations were desensitised to trypsin (3 U.ml -1 ; data not shown), suggesting that all peptides activate PAR 2 . In the Ussing chamber mouse tracheal assay, however, SLCGRL, SLIGRT and LSIGRL, but not SLSGRT, induced I SC increases over similar concentration ranges as SLIGRL.
2-furoyl-LIGRL, however, appeared to be more potent than any of the other active peptides, but with a maximum increase in I SC of only 9.0 ± 3.0 µA.cm -2 at a concentration of 3 µM (Figure 3 ).
Therefore, an apparent rank order of potency of the peptides was 2-furoyl > SLCGRL > SLIGRT = SLIGRL > LSIGRL and SLSGRT inactive (Figure 3) , with 2-furoyl-LIGRL appearing to act as a partial agonist. Threshold concentration for the second phase of the I SC curve to substance P usually occurred at around 10 pM and was maximum at approximately 1 nM ( Figure 5 ). The selective NK 1 R antagonist, SR140333 (100 nM) abolished the first phase of the substance P curve and caused an estimated approximate 1000-fold shift to the right in the second component ( Figure 5 ). SR140333
Involvement of Cl
(100 nM) had no effect on the increase in I SC to a sub-maximum concentration (10 µM) of ATP (97 ± 18 µA.cm -2 control; 95 ± 18 µA.cm -2 SR140333, n = 4). Two further NK 1 R-selective antagonists, GR205171 (10 nM) and GR82334 (0.1 µM) similarly blocked the I SC curve to SLIGRL ( Figure 5 ).
Capsaicin (10 µM) added to both sides of the Ussing tracheal preparation caused an increase in I SC of 32.9 ± 7.3 µA.cm -2 (n = 4) which declined to baseline levels after 30 min, at which time it had no inhibitory effect on the I SC curve to SLIGRL, if anything it appeared to be potentiated although not significantly ( Figure 5) . Also, addition of the CGRP antagonist, CGRP 8-37 (100 µM)
for 20 min to both sides of the preparation had no effect on the increase in I SC to luminal SLIGRL In tension assays in the mouse trachea, the NK 1 R antagonist SR140333 (100 nM) had no inhibitory effect on the relaxation curve to SLIGRL, whereas the biphasic response curve to substance P was abolished by SR140333 ( Figure 6 ). Additionally, in rat thoracic aorta, where substance P failed to cause any mechanical responses (either endothelium-dependent relaxation or contraction; data not shown), SR140333 had no effect on the relaxation curve to SLIGRL and LSIGRL was inactive ( Figure 6 ). Ca 2+ measurement in A549 cells. Substance P (100 nM) caused little if any increase in intracellular Ca 2+ in A549 cells and the response to SLIGRL was unaffected by SR140333, but was inhibited following desensitisation with trypsin (Figure 7 ), confirming the above tension data in the rat thoracic aorta. Clearly SR140333 has no inhibitory effect at PAR 2 .
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Discussion
The results of this study indicate that the supposed selective PAR 2 peptide agonist, SLIGRL, is an agonist of NK 1 R located on the apical surface of epithelial cells of the mouse trachea.
Therefore, given the accepted role of substance P and NK 1 Rs in asthma (Barnes, 1998) , any claims for roles of PAR 2 in inflammatory airway disease that are based solely on data from experiments using SLIGRL or other similar PAR 2 -activating peptides, may need to be reconsidered in light of our study.
Unlike Kunzelmann et al (2005) , we found no change in I SC to the PAR 2 activators trypsin and SLIGRL when they were applied to the basolateral surface of mouse tracheal epithelial cells.
Also, contrary to our findings here, Kunzelmann et al (2005) found no response to apicallyapplied trypsin or SLIGRL, even though, as we reported earlier (Cocks et al., 1999) , they found PAR 2 was predominantly expressed on the apical surface of mouse tracheal epithelial cells. Both the inability of Kunzelmann et al (2005) to demonstrate responses to apically-applied SLIGRL and our inability to similarly show responses to basolaterally-applied SLIGRL, most likely reflect a lack of NK 1 R expressed on the mucosal surface of airway epithelial cells in the strain of mice used by Kunzelmann et al (2005) and the inability of basolateral PAR 2 to couple to Cl -secretion in the strain of mouse (Balb/C) used in our study. (Asokananthan et al., 2002) which has been shown previously to mediate epithelium-dependent relaxation in this tissue (Cocks et al., 1999; Lan et al., 2001; De Campo and Henry, 2005) . Fortner et al (2001b) have claimed that substance P causes similar increases in luminal Cl -conductance in the mouse airway, but that this activity is linked in some way to smooth muscle relaxation, which the same group showed was due to concomitant abluminal release of PGE 2 from the epithelium (Fortner et al., 2001) . A possible simple explanation for this rather confusing concept is that some of the PGE 2 released contraluminally into the wall of the airway activates basolateral EP receptors to increase luminal ion conductance. This idea is supported by our current finding that part of the increase in ion conductance to luminal substance P was inhibited by indomethacin, which abolished the concomitant relaxation and which, like that to ATP, is epithelium-dependent (Kao et al., 1999) . The lack of effect of indomethacin on increases in I SC to SLIGRL observed here is most likely due to the relatively weak efficacy of SLIGRL at luminal synthesis. This possibility is supported by ATP only being able to cause weak epitheliumdependent relaxations in the mouse trachea which, like those for SLIGRL and substance P, are abolished by indomethacin (Moffatt and Cocks, unpublished data) .
Since SLIGRL, 2-furoyl-LIGRL, LSIGRL and SLCGRL are all cationic with arginine at position 5, it is possible that these and other peptides increase I SC indirectly via non-receptor dependent degranulation of mast cells (Stenton et al., 2002) . That the response is blocked by SR140333, however, still implies a role for NK 1 R, which is possible as rat colonic mast cells have been shown to release substantial amounts of substance P in response to anti-IgE which was inhibited by SR140333 (Moriarty et al., 2001) . Such a non-specific action on mast cells is unlikely to explain the current findings, however, for two reasons. First, we found that the mast cell degranulating agent compound 48/80, failed to cause an increase in I SC or affect subsequent I SC responses to SLIGRL (Abey and Cocks, unpublished data). The second reason why mast cells are unlikely to be involved in the increase in I SC to PAR 2 peptides is that capsaicin, which failed to affect I SC increases to SLIGRL in the present study, has been shown to deplete mast cells of substance P (Moriarty et al., 2001) , most likely via activation of vanilloid VR1 receptors (Biro et al., 1998) . Furthermore, another novel R 5 cationic peptide, SLSGRT, failed to cause either an increase in I SC in the mouse trachea or smooth muscle relaxation in both the mouse trachea and rat thoracic aorta. That single amino acid substitutions can markedly modify the binding characteristics of these peptides further argues against a non-specific action of these molecules such as their gross charge.
Substance P and capsaicin both caused increases in I SC in the mouse trachea. Therefore, it is possible that the similar responses to PAR 2 peptides in this preparation were due to their ability to cause release of substance P from sensory nerves, either directly through activation of PAR 2 on sensory nerves (Fiorucci et al., 2001; Kawabata et al., 2001; Su et al., 2005) or indirectly via a mechanism similar to that reported for mast cells (Stenton et al., 2002) . This seems unlikely, however, since sensory neuropeptide depletion with prolonged exposure to capsaicin had no inhibitory effect on the I SC response to SLIGRL. Also, any role for sensory nerves in the I SC response to SLIGRL was further ruled out by the lack of effect of an antagonist (CGRP 8-37 ) of the other major sensory neurotransmitter in the airways, CGRP (Barnes, 1998) . Rather, combined with the different rank order of potencies of 2-furoyl-LIGRL, SLIGRL, LSIGRL, SLIGRT and SLCGRL for ion secretion compared with that for endothelium-dependent nitric oxide production in the rat aorta (Hwa et al., 1996) , the lack of activity of LSIGRL in both the mouse tracheal and rat aortic smooth muscle assays and the selectivity of SR140333 for substance P in the I SC and airway relaxation assays, our data suggest that SLIGRL directly activates NK 1 Rs located on the epithelium.
The biphasic concentration-I SC curve to substance P may reflect two molecular isoforms of NK 1 R that have been shown in molecular recombination studies to be determined by the type of Gprotein each NK 1 R form couples to (Holst et al., 2001) . Also, the high potency of substance P in this assay may reflect high affinity with both isoforms of the receptor. If all of the PAR 2 peptides activated the same isoform of NK 1 R to increase I SC , then some structure-activity can be deduced.
Thus, their rough rank order of potency (2-furoyl-LIGRL > SLCGRL > SLIGRL = SLIGRT > LSIGRL with SLSGRL inactive) indicates that reversal of the first two amino acids diminishes NK 1 R activity, S 3 for I 3 abolishes it, C 3 for I 3 substitution appears to increase it, T 6 for L 6 substitution has little effect and substitution of 2-furoyl for S 1 increases potency, but markedly reduces efficacy. This apparent weak partial agonist activity of 2-furoyl-LIGRL at NK 1 R in the This article has not been copyedited and formatted. The final version may differ from this version. The results presented here allow a closer examination of some recent studies where PAR 2 has been suggested to mediate effects in the airways, but where the pharmacological data present are not always consistent with classic PAR 2 pharmacology (Moffatt, 2004) . In some studies, the nonspecific mechanism of action may account for the findings rather than PAR 2 per se. For example, high micromolar concentrations of PAR 2 -activating peptides have been shown to increase I SC in human airway epithelial cells (Danahay et al., 2001 ), act as a mitogen for airway smooth muscle (Chambers et al., 2000) and activate eosinophils (Miike et al., 2001) . Although trypsin may also elicit a response in these studies, it is often not practically possible to perform cross desensitisation studies to establish that trypsin and peptide activators act via a common mechanism. Furthermore, concentrations of trypsin that are supramaximal for PAR 2 activation, as we found here in the I SC response to trypsin, are often required to elicit a response. Therefore, in the absence of PAR 2 antagonists and the ability to cross-desensitise with trypsin, PAR 2 knockout animals provide the only certain information regarding the role of this receptor in airway inflammation. Thus, Schmidlin et al (2002) showed that the early, but not late, phase of immune cell trafficking into the airway lumen after ovalbumin (OVA) challenge in OVA-sensitised wild type mice was reduced and increased in PAR 2 knockout and PAR 2 over-expressing transgenic mice respectively, suggesting that PAR 2 was indeed involved in this early phase allergic response in the airways. However, unexplained effects of PAR 2 deletion on the production of IgE in response to sensitisation (Schmidlin et al., 2002) may account for this difference.
This article has not been copyedited and formatted. The final version may differ from this version. contractions. The number of experiments conducted for each peptide in the rat thoracic aorta and Ussing chamber assays were; SLSGRT ( , n = 10, n = 7 respectively), LSIGRL ( , n = 3, n = 4 respectively), SLCGRL ( , n = 8, n = 7 respectively), SLIGRT ( , n = 13, n = 6 respectively), SLIGRL ( , n = 9, n = 13 respectively) and 2-furoyl-LIGRL ( , n = 6, n = 5 respectively). All data points are presented as means ± SEM. 
